4//SEC Filing
Regnante Keith 4
Accession 0001209191-23-036261
CIK 0001664710other
Filed
Jun 11, 8:00 PM ET
Accepted
Jun 12, 4:13 PM ET
Size
21.5 KB
Accession
0001209191-23-036261
Insider Transaction Report
Form 4
Regnante Keith
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2023-06-09$47.25/sh−2,579$121,858→ 0 total - Sale
Common Stock
2023-06-09$45.03/sh−15,993$720,165→ 4,007 total - Sale
Common Stock
2023-06-09$46.46/sh−1,428$66,345→ 2,579 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-06-08−20,000→ 113,622 totalExercise: $16.00Exp: 2030-04-06→ Common Stock (20,000 underlying) - Sale
Common Stock
2023-06-08$47.66/sh−17,301$824,566→ 2,699 total - Sale
Common Stock
2023-06-08$48.65/sh−2,699$131,306→ 0 total - Exercise/Conversion
Common Stock
2023-06-09$16.00/sh+20,000$320,000→ 20,000 total - Exercise/Conversion
Common Stock
2023-06-08$16.00/sh+20,000$320,000→ 20,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-06-09−20,000→ 93,622 totalExercise: $16.00Exp: 2030-04-06→ Common Stock (20,000 underlying)
Footnotes (7)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.12 to $48.095 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.995 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.015 to $47.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.015 to $47.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001682068
Filing Metadata
- Form type
- 4
- Filed
- Jun 11, 8:00 PM ET
- Accepted
- Jun 12, 4:13 PM ET
- Size
- 21.5 KB